title: Peripheral blood-derived stem cell collections for use in autologous transplantation after high dose chemotherapy: an alternative approach.
abstract: Peripheral blood-derived hematopoietic stem cells (PBHSC) can be utilized to reconstitute hematopoiesis in patients after high dose myeloablative chemotherapy. We have performed PBHSC reinfusion in 18 patients who have or had a history of tumor involving the bone marrow or a hypocellular bone marrow. The PBHSC were collected by continuous flow leukapheresis and subsequently cryopreserved. A median of 31.9 X 10(9) (range 18 X 10(9)-67.2 X 10(9)) mononuclear cells or a median of 4.85 X 10(8) mononuclear cells/kg (range 2.7 X 10(8)-11.0 X 10(8)) were collected. Fifteen patients had in vitro assays of granulocyte-monocyte colony-forming cells (CFU-GM) performed with a median of 2.7 X 10(4) (range 0-11.5 X 10(4)) CFU-GM/kg. To date, of the 18 patients collected, all have undergone high dose chemotherapy and PBHSC reinfusion. For the evaluable patients, granulocyte recovery (greater than 500 X 10(6)/ml) has occurred in a median of 15 days and platelet recovery (greater than 50 X 10(9)/ml without transfusion support) has occurred in a median of 43 days. Four patients have had prolonged thrombocytopenia and still require platelet transfusion at 80+, 97+, 124+, and 270+ days. PBHSC collection is safe and effective for hematopoietic reconstitution after high dose chemotherapy in the majority of patients; however incomplete hematopoietic reconstitution has been observed in 4/18 evaluable patients. This procedure requires further investigation.
authors.affiliation: Autologous Bone Marrow Transplant Program, University of Chicago, IL 60637.
authors.forename: S F
authors.initials: SF
authors.lastname: Williams
authors.forename: J D
authors.initials: JD
authors.lastname: Bitran
authors.forename: J M
authors.initials: JM
authors.lastname: Richards
authors.forename: P J
authors.initials: PJ
authors.lastname: DeChristopher
authors.forename: E
authors.initials: E
authors.lastname: Barker
authors.forename: J
authors.initials: J
authors.lastname: Conant
authors.forename: H M
authors.initials: HM
authors.lastname: Golomb
authors.forename: A R
authors.initials: AR
authors.lastname: Orlina
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001855:Bone Marrow Diseases / Q000209:etiology / Q000473:pathology / Q000601:surgery*; D003114:Colony-Forming Units Assay; D015925:Cryopreservation; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000473:pathology; D006801:Humans; D007937:Leukapheresis / Q000379:methods; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*